Predictive low-glucose suspend system and glycemic variability

Basit Öğe Kaydı
dc.authoridatik-altınok, yasemin/0000-0001-5851-1012
dc.authoridEr, Eren/0000-0003-4770-0365
dc.authorscopusid57220114978
dc.authorscopusid57216201215
dc.authorscopusid57220119294
dc.authorscopusid56203491900
dc.authorscopusid57202134466
dc.authorscopusid15060967600
dc.authorscopusid57193881141
dc.authorwosidatik-altınok, yasemin/A-5858-2019
dc.authorwosidata, aysun/GSD-7045-2022
dc.contributor.authorEvin, Ferda
dc.contributor.authorAta, Aysun
dc.contributor.authorEr, Eren
dc.contributor.authorDemir, Gunay
dc.contributor.authorcetin, Hafize
dc.contributor.authorAltinok, Yasemin Atik
dc.contributor.authorozen, Samim
dc.date.accessioned2023-01-12T19:51:44Z
dc.date.available2023-01-12T19:51:44Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractIntroduction Predictive low-glucose suspend (PLGS) system helps prevent hypoglycemia. Aim To evaluate the effect of PLGS therapy on GV and percentage of time in range (TIR), time below range (TBR), and time above range (TAR) in pediatric type 1 diabetic patients. Method HbA(1c), coefficient of variation (CV). standard deviation (SD). and percentage of TIR, TBR, and TAR were evaluated in type 1 diabetic (T1D) pediatric patients followed up between Jan 2016 and Mar 2020 using PLGS system. Results Mean ages of diagnosis and duration of diabetes were 6.7 +/- 4.1 and 8.2 +/- 4.3 years, respectively. Nineteen of the patients were male (46.3%) and 22 were female (53.7%). Twenty-two (53.7%) of the patients were using low-glucose suspend system and 19 (46.3%) were on multiple daily injection therapy (MDI). On PLGS therapy, the 3rd, 6th, 9th, and 12th months' HbA(1c) of patients were not different from previous years' mean HbA(1c) in all participants. In the 3rd, 6th, 9th, and 12th months of PLGS therapy, % of TIR were 65.34 +/- 14.75%, 65.80 +/- 14.67%, 66.58 +/- 11.21%, and 70.04 +/- 10.16%, respectively (p = 0.01). Although statistically insignificant, CV decreased from 36.33 to 34.30% and SD decreased from 60.14 to 58.60 in the 1-year follow-up period (p = 0.062 and p = 0.246). Conclusion With PLGS therapy, TIR was > 70% and the time spent in hypoglycemia was very low.en_US
dc.identifier.doi10.1007/s13410-021-00957-1
dc.identifier.endpage282en_US
dc.identifier.issn0973-3930
dc.identifier.issn1998-3832
dc.identifier.issn0973-3930en_US
dc.identifier.issn1998-3832en_US
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85107404300en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage276en_US
dc.identifier.urihttps://doi.org/10.1007/s13410-021-00957-1
dc.identifier.urihttps://hdl.handle.net/11454/76320
dc.identifier.volume42en_US
dc.identifier.wosWOS:000657560000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Indiaen_US
dc.relation.ispartofInternational Journal Of Diabetes In Developing Countriesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInsulin pump therapyen_US
dc.subjectPredictive low-glucose suspenden_US
dc.subjectTime in rangeen_US
dc.subjectGlycemic variabilityen_US
dc.subjectCoefficient of variationen_US
dc.subjectInsulin Suspensionen_US
dc.subjectHypoglycemiaen_US
dc.subjectConfidenceen_US
dc.subjectReductionen_US
dc.subjectRangeen_US
dc.subjectTimeen_US
dc.subjectRisken_US
dc.subject640gen_US
dc.titlePredictive low-glucose suspend system and glycemic variabilityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu